Next EU COVID-19 Vaccine Contracts Will Take On ‘Lessons Learned’ In Capacity And Supply
EMA OKs Boost In Production Capacity For Pfizer/BioNTech & Moderna
The European Commission appears to be favoring mRNA vaccines in its negotiations with companies on the next generation of COVID-19 vaccine contracts. Manufacturing finally appears to be gaining momentum, and the health commissioner claims the EU has “turned the corner” with its vaccination programs.
You may also be interested in...
Coronavirus Notebook: EU Launches Vaccine Monitoring Scheme, AZ Vows To Defend Itself Against Legal Action
The EMA has issued updated safety advice on AstraZeneca’s COVID-19 vaccine, Vaxzevria, Valneva has decided to pursue vaccine supply deals with individual member states after a falling out with the European Commission, and Kazakhstan has begun administering the first doses of its domestically produced vaccine, QazVac.
Pfizer/BioNTech is emerging as the EU’s partner of choice for COVID-19 vaccines, but others could also benefit.
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.